Rapid Generation of Retinal Pigmented Epithelium for Retinal Disease Therapy
Tech ID: 22139 / UC Case 2012-019-0
A novel method for rapid and efficient differentiation of human embryonic stem cells into retinal pigmented epithelium.
Retinal Pigmented Epithelium (RPE) cells can be created from human embryonic and induced pluripotent stem cells. It has been shown, however, that the transformation of these stem cells into RPE is inefficient and very time consuming. Research into degenerative retinal diseases would benefit greatly from a more timely and efficient method for producing RPE from human embryonic stem cells.
Researchers at the University of California, Santa Barbara have developed a novel method for rapid and efficient differentiation of human embryonic stem cells into retinal pigmented epithelium. This method yields RPE in the majority of stem cells treated in only half of the time documented for the most efficient methods. The speed and efficiency of the method gives it the potential to significantly advance the fields of research dealing with the causes and therapies for degenerative retinal diseases (e.g. age-related macular degeneration).
- Highly efficient and rapid conversion of human embryonic stem cells to retinal tissue cells
- A potentially unlimited source of RPE for transplant therapy from human embryonic and induced pluripotent stem cells
- Cellular therapy for degenerative retinal diseases
- Degenerative retinal disease research
This technology is available for licensing.
|Patent Cooperation Treaty||Published Application||WO2013/184809||12/12/2013||2012-019|
Additional Patent Pending
- Buchholz, David E.
- Clegg, Dennis O.
indpharma, retinal disease, stem cell
ADDITIONAL TECHNOLOGIES BY THESE INVENTORS
PEOPLE WHO VIEWED THIS ALSO VIEWED THESE TECHNOLOGIES BY OTHER INVENTORS
- Identifying Motifs Using Next-Generation Sequencing Experiments
- Novel Peptide Ligation Process Under Mild, Reagent-Free Conditions
- Photonic Gene Circuits
- Donor-Acceptor Rod-Coil Diblock Copolymer based on P3HT containing fullerene (C¬60)
- Wnt and Frizzled Receptors as Targets of Immunotherapy in Human Cancers